What prophylactic measures can be used to prevent yeast infection in a 76‑year‑old woman taking dapagliflozin (Farxiga)?

Prophylaxis for Yeast Infections in a 76-Year-Old Woman on Farxiga

For a 76-year-old woman on Farxiga who develops recurrent vulvovaginal yeast infections (≥4 episodes per year), use fluconazole 150 mg once weekly for 6 months after initial treatment. If she has not yet developed recurrent infections but you're concerned about prevention, the evidence does not support routine prophylaxis—instead, treat infections as they occur and only initiate suppressive therapy if she meets criteria for recurrent disease 1.

Understanding the Risk

Farxiga (dapagliflozin) significantly increases the risk of genital mycotic infections in women. The FDA label clearly documents that female genital mycotic infections occur in 6.9-8.4% of women taking Farxiga versus only 1.5% on placebo 2. This 4-6 fold increased risk is directly related to the drug's mechanism—it causes glucosuria (glucose in urine), which creates an ideal environment for yeast growth. Women with a prior history of yeast infections are at even higher risk 2.

When to Start Prophylaxis

Do not start prophylaxis unless she develops recurrent vulvovaginal candidiasis, defined as ≥4 symptomatic episodes within one year 1. The IDSA guidelines are explicit that chronic suppressive therapy is "usually unnecessary" and should only be used for patients with documented recurrent infection 1.

The Prophylactic Regimen

If she meets criteria for recurrent infection:

1. Induction phase: Treat the acute infection first with either:

   • Topical azole for 10-14 days, OR
   • Oral fluconazole 150 mg for 10-14 days 1

2. Maintenance phase: Once symptom-free and cultures are negative:

   • Fluconazole 150 mg once weekly for at least 6 months (strong recommendation; high-quality evidence) 1
   • This achieves symptom control in >90% of patients 1

3. Alternative if fluconazole is not feasible:

   • Clotrimazole 200 mg vaginal cream twice weekly, OR
   • Clotrimazole 500 mg vaginal suppository once weekly 1

Important Caveats for This Patient

Age considerations: At 76 years old, she may have additional risk factors:

• If she's on diuretics or has volume depletion risk, Farxiga increases dehydration risk, which can concentrate urine glucose further 2
• Ensure adequate hydration to potentially reduce glucosuria concentration
• Monitor for urinary tract infections, which also increase with Farxiga (4.3-5.7% vs 3.7% placebo) 2

Duration of prophylaxis: After stopping the 6-month maintenance regimen, expect a 40-50% recurrence rate 1. If infections recur after stopping prophylaxis, consider restarting weekly fluconazole or discussing whether continuing Farxiga is appropriate given her quality of life.

What NOT to Do

• Do not use prophylaxis before the first infection occurs—there's no evidence supporting this approach
• Do not use daily antifungals—weekly dosing is the evidence-based regimen
• Do not rely on over-the-counter treatments for prophylaxis—these are for acute treatment only 2

Monitoring Strategy

When she develops symptoms (pruritus, vaginal discharge, irritation):

• Confirm diagnosis with wet mount or culture before treating 1, 3
• If symptoms don't resolve with over-the-counter azoles within a few days, she needs evaluation 2
• Consider non-albicans species (especially C. glabrata) if infections are refractory to standard azole therapy 1

Alternative Consideration

If yeast infections become severely problematic despite prophylaxis and significantly impact her quality of life, discuss with her prescribing physician whether the benefits of Farxiga outweigh this adverse effect. However, given Farxiga's cardiovascular and renal protective benefits in appropriate patients, this should be a careful risk-benefit discussion rather than an automatic discontinuation.